Given that BCL-2 is emerging as one of the main prognostic predictors in DLBCL treated with anthracycline-containing regimens, we first investigated the impact of BCL-2 overexpression on the activity of chemotherapeutic drugs inhibiting ribosome biogenesis. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.